However, in the BICC1 high group, the anti-LCN2 antibody, but not Bevacizumab, enhanced the antitumor effect of GEM, and efficiently inhibited tumor angiogenesis and promoted vascular normalization, resulting in a remarkable anti-tumor effect (Fig. 7b–f, Supplementary Fig. 24). Here, LCN2 is linked to neoplasm.